What to Charge for a GLP-1 Program in 2026

The floor: manufacturer direct-pay pricing

Novo Nordisk's NovoCare Pharmacy sells Wegovy direct to cash-pay patients at $349 per month across standard doses (the 7.2 mg high dose runs $399), with a $199-per-month introductory offer on the two starting doses running through December 2026. That $349 is itself the second cut: the channel launched in March 2025 at $499, and the reduction was announced in November 2025.

Eli Lilly's LillyDirect channel prices Zepbound single-dose vials at $299 (2.5 mg), $399 (5 mg), and $449 (higher doses) after a December 2025 cut, with multi-dose pens committed to the same band under Lilly's November 2025 pricing agreement with the U.S. government. And the first oral GLP-1 for weight loss, approved in spring 2026, entered at $149 per month for its lowest dose (up to $399 at higher doses), which put a triple-digit floor under the whole category.

The business meaning: the manufacturers set a visible reference price and moved it down roughly 40 percent inside a year. A program whose pitch is access to the medication is competing with the manufacturer's own pipe; a program whose pitch is the care around the medication has something the pipe does not sell.

The floor's trajectory, sourced below: $499 at the channel's March 2025 launch, $349 by November 2025, a $199 introductory tier through 2026, and a $149 oral entry point in spring 2026. Price architectures built on medication scarcity are done; the ones that survive sell the program, not the pill.

What the major telehealth programs charge

The dominant DTC architecture is medication plus membership. Ro charges a $39 first month and then $149 per month for its membership, with medication billed at cash prices it states match the manufacturer channels. LifeMD runs the same shape: $39 first month, then a $149 monthly program fee with medication separate. The membership covers the clinical relationship, coaching, and program machinery; the medication line rides the manufacturer floor.

Below the branded floor sits the compounded lane where programs still operate one: Noom markets a compounded 'microdose' semaglutide offering from $79 per month with medication included. Compounded pricing is only part of that story: post-shortage, compounded GLP-1 supply rests on narrow, contested legal grounds, several large players exited compounded semaglutide for new patients in 2026, and any program considering the lane needs its pharmacy's written legal basis first (our compounded-GLP-1 guides cover the posture in depth). Compounded medications are not FDA approved, are prescribed only at a licensed clinician's discretion, and not all patients qualify.

Put together, the visible 2026 market band runs roughly $149 to $449 per month for medication depending on product and dose, plus membership fees around $149 per month where programs charge them separately (both Ro and LifeMD publish that number, with discounted $39 first months). The 2024-2025 era's wider, higher band (compounded offers from the mid-$100s, branded bundles far higher) compressed from both ends as manufacturer pricing fell.

The three pricing architectures, and who each fits

Architecture one, medication plus membership: the patient sees two lines (a program fee and a medication price near the public floor). It is transparent and floor-proof (manufacturer cuts pass through instead of stranding you), and it makes your membership earn its fee visibly every month. It fits programs whose care layer is genuinely rich.

Architecture two, the all-in bundle: one monthly price with medication included. It is the simplest patient promise, it removes the month-three cost shock that kills retention, and it puts supply economics on the program side, which only works when the program's medication costs are flat and knowable (this is the architecture EmbedCare's flat product rates with medication included are built for, with the retail set by you). It fits brands selling a complete experience under one number.

Architecture three, the low-price compounded lane: a sub-floor price built on compounded supply. It can be run lawfully within the narrow current posture, and it carries the regulatory homework, the supply fragility, and the marketing constraints (no equivalence claims, explicit disclosures) that the rest of this site documents; it fits operators who have actually done that homework, and traps everyone else.

Setting your number: the four-input framework

Input one, your true per-patient cost: on a platform, the flat product rate (medication included or not); on an assembled stack, medication cost per fill plus visit costs plus operations. Input two, the public reference: what your patient sees at the manufacturer channel for the same product, because they will look. Input three, the competitive band above: where the membership-plus-medication programs land all-in. Input four, your articulable value: the concrete things your program does that the floor does not (the care team, the convenience, the community, the brand relationship), each of which you can name in a sentence without an outcome promise.

Then price where the arithmetic and the story agree: above your costs by a margin that funds real service, within sight of the band unless your value story genuinely carries more, and never on the assumption the patient has not seen the floor. Two disclosure rules are non-negotiable whatever you charge: the full program cost visible before checkout (hidden medication costs are a named deception pattern in FTC telehealth enforcement), and cancellation as easy as signup under the click-to-cancel rules. Honest pricing is also, conveniently, the chargeback-minimizing strategy.

• Know your true all-in cost per patient per month before choosing any retail
• Assume every patient has seen the manufacturer's cash price, because they have
• Price the program's value, not medication access: access is the floor's job now
• Full cost visible before checkout; cancellation as easy as signup
• Revisit quarterly: this market moved its floor twice in twelve months

Where EmbedCare fits

EmbedCare partners run architecture two on rails: flat product rates with medication included on GLP-1 programs, fixed in a signed partner agreement, with the retail set by the partner and the spread above the rate kept by the partner. The platform's owned pharmacy supply is what makes an all-in retail knowable in advance, and the self-serve Launch tier starts at $495/mo. A demo prices your specific program in writing against your audience and product mix, which is the only version of pricing advice worth acting on.